Objectives: Clinical studies have demonstrated that circulating cytokine profiles may differ between alexithymic and non-alexithymic subjects. We examined whether the levels of adiponectin (μg/ml) and resistin (ng/ml) are independently related to alexithymic features in a population-based sample. Methods: In 2005, clinical data including laboratory assessments were obtained from a sub-sample (n = 308) of the Kuopio Depression Study general population study including subjects aged 25-64 years. Based on the Toronto Alexithymia Scale score in 1998, 1999, 2001 and 2005, a group of subjects with high alexithymic features (n = 85) was formed and compared with non-alexithymic controls (n = 206). Results: Serum adiponectin levels were significantly lower in subjects with alexithymic features than in non-alexithymic control subjects. No difference was found in resistin levels. Similarly, in a logistic regression model adjusted for age, gender and body mass index (BMI), lowered levels of adiponectin, but not resistin, were associated with an increased likelihood of belonging to the group with alexithymic features. Further adjustments for cardiovascular risk factors (i.e. smoking, BMI, metabolic syndrome, alcohol use, and coronary heart disease), depressive symptoms (Hamilton Depression Rating Scale with 17 items) and the use of antidepressants in addition to age and gender did not change these patterns. Conclusions: Our findings suggest that a disturbed anti-inflammatory balance may characterize alexithymia. In addition, our results widen the concept of alexithymia and highlight the role of immune system alterations and stress in alexithymic individuals.

Keywords:
Alexithymia, Depression, Immune systems
1.
Sifneos PE: The prevalence of ‘alexithymic' characteristics in psychosomatic patients. Psychother Psychosom 1973;22:255-262.
2.
Pinna F, Pirarda S, Orru W, Velluzzi F, Loviselli A, Carpiniello B: Obesity, alexithymia and psychopathology: a case-control study. Eat Weight Disord 2011;3:164-170.
3.
Beresnevaite M, Taylor GJ, Bagby RM: Assessing alexithymia and type A behaviour in coronary heart disease patients: a multimethod approach. Psychother Psychosom 2007;76:186-192.
4.
Tolmunen T, Lehto SM, Heliste M, Kurl S, Kauhanen J: Alexithymia is associated with increased cardiovascular mortality in middle-aged Finnish men. Psychosom Med 2010;72:187-191.
5.
Mandarelli G, Tarsitani L, Ippoliti F, Covotta F, Zerella MP, Mirigliani A, Biondi M: The relationship between alexithymia and circulating cytokine levels in subjects undergoing upper endoscopy. Neuroimmunomodulation 2011;18:37-44.
6.
Honkalampi K, Lehto S, Koivumaa-Honkanen H, Hintikka J, Niskanen L, Valkonen-Korhonen M, Viinamäki H: Alexithymia and tissue inflammation. Psychother Psychosom 2011;80:359-364.
7.
Pedrosa GF, Nickel M, Ridout N, Schwarz MJ, Schoechlin C, Schmidmaier R: Alexithymia and interleukin variations in somatoform disorder. Neuroimmunomodulation 2007;14:235-242.
8.
Uher T, Bob P: Cerebrospinal fluid IL-8 levels reflect symptoms of alexithymia in patients with non-inflammatory neurological disorders. Psychoneuroendocrinology 2011;36:1148-1153.
9.
Guilbaund O, Corcos M, Hjalmarsson L, Loas G, Jeammet P: Is there a psychoneuroimmunological pathway between alexithymia and immunity? Immune and physiological correlates of alexithymia. Biomed Pharmacother 2003;57:292-295.
10.
Goldstein BI, Kemp DE, Soczynska JK, McIntyre RS: Inflammation and phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry 2009;70:1078-1090.
11.
Raison CL, Capuron L, Miller AH: Cytokines sing the blues: inflammation and pathogenesis of depression. Trends Immunol 2006;27:24-31.
12.
Leo R, Di Lorenzo G, Tesauro M, Cola C, Fortuna E, Zanasi M, Troisi A, Siracusano A, Lauro R, Romeo F: Decreased plasma adiponectin (μg/ml) concentration in major depression. Neurosci Lett 2006;407:211-213.
13.
Lehto SM, Huotari A, Niskanen L, Herzig KH, Tolmunen T, Koivumaa-Honkanen H, Honkalampi K, Ruotsalainen H, Herzig K-H, Viinamäki H, Hintikka J: Serum adiponectin and resistin levels in major depressive disorder. Acta Psychiatr Scand 2010;121:209-215.
14.
Tilg H, Moschen AR: Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006;10:772-783.
15.
Krysiak R, Handzlik G, Okopien OR: The role of adipokines in connective tissue diseases. Eur J Nutr 2012;51:513-528.
16.
Honkalampi K, Hintikka J, Tanskanen A, Lehtonen J, Viinamäki H: Depression is strongly associated with alexithymia in the general population. J Psychosom Res 2000;48:99-104.
17.
Viinamäki H, Heiskanen T, Lehto SM, Niskanen L, Koivumaa-Honkanen H, Tolmunen T, Honkalampi K, Saharinen T, Haatainen K, Hintikka J: Depressive symptoms are associated with metabolic syndrome in men. Acta Psychiatr Scand 2009;120:23-29.
18.
Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J: An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-571.
19.
Bagby RM, Parker JDA, Taylor GJ: The twenty-item Toronto Alexithymia Scale-I: item selection and cross-validation of the factor structure. J Psychosom Res 1994;38:23-32.
20.
Koivumaa-Honkanen H, Honkanen R, Antikainen R, Hintikka J, Laukkanen E, Honkalampi K, Viinamäki H: Self-reported life satisfaction and recovery from depression in a 1-year prospective study. Acta Psychiatr Scand 2001;103:38-44.
21.
Joukamaa M, Miettunen J, Kokkonen P, Koskinen M, Julkunen J, Kauhanen J, Jokelainen J, Veijola J, Läksy K, Järvelin MR: Psychometric properties of the Finnish 20-item Toronto Alexithymia Scale. Nord J Psychiatry 2001;55:123-127.
22.
Bagby RM, Taylor GJ: Measurement and validation of the alexithymia construct; in Taylor GJ, Bagby RM, Parker JDA (eds): Disorders of Affect Regulation. Alexithymia in Medical and Psychiatric Illness. Cambridge, Cambridge University Press, 1997, pp 47-66.
23.
Hamilton M: A rating scale of depression. J Neurol Neurosurg Psychiatry 1960;23:52-62.
24.
Taylor VH, MacQueen GM: The role of adipokines in understanding the associations between obesity and depression. J Obes DOI: 10.1155/2010/748048.
25.
Martin JB, Pihl RO: Influence of alexithymic characteristics on physiological and subjective stress responses in normal individuals. Psychother Psychosom 1986;45:66-77.
26.
Sepede G, Racciaitti D, Gorgoretti V, Pizziogallo E, Onofrj M, Giannantonio M, Niolu C, Salerno RM, Gambi F: Psychophysical distress and alexithymic traits in chronic fatigue syndrome with and without comorbid depression. Int J Immunopathol Pharmacol 2011;24:1017-1025.
27.
Bardosa F, Mota C, Patricio P, Alcantara C, Ferreira C, Barbosa A: The relationship between alexithymia and physiological factors in systemic lupus erythematosus. Compr Psychiatry 2011;53:754-762.
28.
Fukunishi I, Sei H, Morita Y, Rahe RH: Sympathetic activity in alexithymics with mother's low care. J Psychosom Res 1999;46:579-589.
29.
De Timary P, Roy E, Luminet O, Fillée C, Mikolajczak M: Relationship between alexithymia, alexithymia factors and salivary cortisol in men exposed to a social stress test. Psychoneuroendocrinology 2008;33:1160-1164.
30.
Declercq F, Vanhaule S, Deheergher J: Alexithymia and posttraumatic stress: subscales and symptom clusters. J Clin Psychol 2010;66:1079-1089.
31.
Da Ros A, Vinai P, Gentile N, Forza G, Cardetti S: Evaluation of alexithymia and depression in severe obese patients not affected by eating disorders. Eat Weight Disord 2011;16:24-29.
32.
Choi KM, Ryu OH, Lee KW, Kim HY, Seo JA, Kim SG, Kim NH, Choi DS, Baik SH: Serum adiponectin, interleukin-10 levels and inflammatory markers in the metabolic syndrome. Diabetes Res Clin Pract 2007;75:235-240.
33.
Singh RB, Gupta S, Dherange P, De Meester F, Wilczynska A, Alam SE, Pella D, Wilson DW: Metabolic syndrome: a brain disease. Can J Physiol Pharmacol 2012;90:1171-1183.
34.
De Haan H, Joonsten E, Wijdeveld T, Boswinkel P, van der Palen J, De Jong C: Alexithymia is not a stable trait in patients with substance use disorder. Psychiatry Res 2012;198:123-129.
35.
Luminet O, Bagby PM, Taylor GJ: An evaluation of the absolute and relative stability of alexithymia in patients with major depression. Psychother Psychosom 2001;70:254-260.
36.
Vogelzangs N, Duivis HE, Beekman ATF, Klutt C, Neuteboom J, Hoogendijk W, Smit JH, de Jonge P, Penninx BWJH: Association of depressive disorders, depression characteristics and antidepressive medication with inflammation. Transl Psychiatry 2012;2:e79.
37.
Kaplan RC, Ho GY, Xue X, Rajpathak S, Cushman M, Rohan TE, Strickler HD, Scherer PE, Anastos K: Within-individual stability of obesity-related biomarkers among women. Cancer Epidemiol Biomarkers Prev 2007;16:1291-1293.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.